Background
EORTC 22952-26001: Phase III, open-label, randomized multicenter trial. 359 patients with 1–3 brain metastases who had undergone complete resection or received SRS were randomized to adjuvant WBRT vs observation. Enrolled Oct 1996–Jan 2004 at 77 centers. WBRT 30 Gy in 10 fractions. Primary endpoint: time to WHO performance status (PS) deterioration ≥2 points.
Interventions and follow up
Arm A: Adjuvant WBRT 30 Gy in 10 fractio
Arm B: Observatio
Primary endpoint: Time to WHO PS deterioration ≥2 points (functional independence)
mFollow up: Median not specified (long-term follow-up paper is Soffietti 2013)
Arm B: Observatio
Primary endpoint: Time to WHO PS deterioration ≥2 points (functional independence)
mFollow up: Median not specified (long-term follow-up paper is Soffietti 2013)
Results
Intracranial relapse at 2 years (post-SRS): 33% WBRT vs 67% observation
Intracranial relapse at 2 years (post-surgery): 48% WBRT vs 78% observation
OS (median): 10.9 months WBRT vs 10.7 months observation — no difference
Time to PS deterioration: No significant difference (median 9.5 vs 9.9 months)
Intracranial relapse at 2 years (post-surgery): 48% WBRT vs 78% observation
OS (median): 10.9 months WBRT vs 10.7 months observation — no difference
Time to PS deterioration: No significant difference (median 9.5 vs 9.9 months)
Adverse events
Main adverse events: WBRT associated with acute fatigue, alopecia. Neurologic death rate similar between arms. No difference in functional independence despite improved brain control.
Conclusions
Adjuvant WBRT after complete resection or SRS of 1–3 brain metastases substantially reduced intracranial relapse but did not improve OS or preservation of functional independence. WBRT after SRS or resection provides brain control at the cost of cognitive side effects, without survival benefit — supporting observation/surveillance strategies after local treatment.
Key Limitations
Key Limitations: PS deterioration as primary endpoint is a relatively crude measure — it cannot detect subtle cognitive changes from WBRT. No formal neurocognitive testing. Longer-term QoL analysis (Soffietti 2013, JCO) later showed WBRT had worse QoL at 9 months. As salvage treatment improved (modern era), the rationale for adjuvant WBRT to prevent future need for salvage became weaker. Different from Alliance N0574 which directly compared SRS ± WBRT (rather than adjuvant WBRT after complete local treatment).
Clinical Context
EORTC 22952 confirmed that WBRT improves intracranial control but not survival or functional independence after successful local treatment. This — combined with MD Anderson (2009) and N0574 (2016) cognitive data — supported the paradigm shift away from adjuvant WBRT toward SRS-only approaches with MRI surveillance. Current ASCO guidelines: for 1–4 BM after resection/SRS, omit WBRT and use SRS to cavity + surveillance.
References